Literature DB >> 8914774

Epitope mapping of the variable repetitive region with the MB antigen of Ureaplasma urealyticum.

X Zheng1, K Lau, M Frazier, G H Cassell, H L Watson.   

Abstract

One of the major surface structures of Ureaplasma urealyticum recognized by antibodies of patients during infection is the MB antigen. Previously, we showed by Western blot (immunoblot) analysis that any one of the anti-MB monoclonal antibodies (MAbs) 3B1.5, 5B1.1, and 10C6.6 could block the binding of patient antibodies to MB. Subsequent DNA sequencing revealed that a unique six-amino-acid direct tandem repeat region composed the carboxy two-thirds of this antigen. In the present study, using antibody-reactive peptide scanning of this repeat region, we demonstrated that the amino acids defining the epitopes for MAbs 3B1.5 5B1.1 and 10C6.6 are EQP, GK, and KEQPA, respectively. Peptide scanning analysis of an infected patient's serum antibody response showed that the dominant epitope was defined by the sequence PAGK. Mapping of these continuous epitopes revealed overlap between all MAb and patient polyclonal antibody binding sites, thus explaining the ability of a single MAb to apparently block all polyclonal antibody binding sites. We also show that a single amino acid difference in the sequence of the repeats of serovars 3 and 14 accounts for the lack of reactivity with serovar 14 of two of the serovar 3-specific MAbs. Finally, the data demonstrate the need to obtain the sequences of the mba genes of all serovars before an effective serovar-specific antibody detection method can be developed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8914774      PMCID: PMC170446          DOI: 10.1128/cdli.3.6.774-778.1996

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  15 in total

1.  Systematic fractionation of serum antibodies using multiple antigen homologous peptides as affinity ligands.

Authors:  G Tribbick; B Triantafyllou; R Lauricella; S J Rodda; T J Mason; H M Geysen
Journal:  J Immunol Methods       Date:  1991-06-03       Impact factor: 2.303

2.  Ureaplasma and mycoplasma CNS infections in newborn babies.

Authors:  K B Waites; D T Crouse; G H Cassell
Journal:  Lancet       Date:  1990-03-17       Impact factor: 79.321

3.  The antigenic index: a novel algorithm for predicting antigenic determinants.

Authors:  B A Jameson; H Wolf
Journal:  Comput Appl Biosci       Date:  1988-03

Review 4.  Prediction of the secondary structure of proteins from their amino acid sequence.

Authors:  P Y Chou; G D Fasman
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1978

5.  Association of Ureaplasma urealyticum infection of the lower respiratory tract with chronic lung disease and death in very-low-birth-weight infants.

Authors:  G H Cassell; K B Waites; D T Crouse; P T Rudd; K C Canupp; S Stagno; G R Cutter
Journal:  Lancet       Date:  1988-07-30       Impact factor: 79.321

6.  Variable antigens of Ureaplasma urealyticum containing both serovar-specific and serovar-cross-reactive epitopes.

Authors:  H L Watson; D K Blalock; G H Cassell
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

7.  Mycoplasmal infections of cerebrospinal fluid in newborn infants from a community hospital population.

Authors:  K B Waites; L B Duffy; D T Crouse; M E Dworsky; M J Strange; K G Nelson; G H Cassell
Journal:  Pediatr Infect Dis J       Date:  1990-04       Impact factor: 2.129

8.  The antigenicity of myoglobin-related peptides synthesised on polyacrylamide and polystyrene resin supports.

Authors:  P T Shi; J P Riehm; P E Todd; S J Leach
Journal:  Mol Immunol       Date:  1984-06       Impact factor: 4.407

9.  Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide.

Authors:  E A Emini; J V Hughes; D S Perlow; J Boger
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

10.  Small repeating units within the Ureaplasma urealyticum MB antigen gene encode serovar specificity and are associated with antigen size variation.

Authors:  X Zheng; L J Teng; H L Watson; J I Glass; A Blanchard; G H Cassell
Journal:  Infect Immun       Date:  1995-03       Impact factor: 3.441

View more
  6 in total

1.  Simple method for determining biovar and serovar types of Ureaplasma urealyticum clinical isolates using PCR-single-strand conformation polymorphism analysis.

Authors:  D Pitcher; M Sillis; J A Robertson
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

Review 2.  The Human Ureaplasma Species as Causative Agents of Chorioamnionitis.

Authors:  Emma L Sweeney; Samantha J Dando; Suhas G Kallapur; Christine L Knox
Journal:  Clin Microbiol Rev       Date:  2016-12-14       Impact factor: 26.132

3.  Ureaplasma urealyticum biovar determination in women attending a family planning clinic in Guiné-Bissau, using polymerase chain reaction of the multiple-banded antigen gene.

Authors:  D Domingues; L Távora Tavira; A Duarte; A Sanca; E Prieto; F Exposto
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

4.  The severity of chorioamnionitis in pregnant sheep is associated with in vivo variation of the surface-exposed multiple-banded antigen/gene of Ureaplasma parvum.

Authors:  Christine L Knox; Samantha J Dando; Ilias Nitsos; Suhas G Kallapur; Alan H Jobe; Diane Payton; Timothy J M Moss; John P Newnham
Journal:  Biol Reprod       Date:  2010-06-02       Impact factor: 4.285

5.  Comparative genome analysis of 19 Ureaplasma urealyticum and Ureaplasma parvum strains.

Authors:  Vanya Paralanov; Jin Lu; Lynn B Duffy; Donna M Crabb; Susmita Shrivastava; Barbara A Methé; Jason Inman; Shibu Yooseph; Li Xiao; Gail H Cassell; Ken B Waites; John I Glass
Journal:  BMC Microbiol       Date:  2012-05-30       Impact factor: 3.605

6.  Ureaplasma Species Multiple Banded Antigen (MBA) Variation Is Associated with the Severity of Inflammation In vivo and In vitro in Human Placentae.

Authors:  Emma L Sweeney; Suhas G Kallapur; Simone Meawad; Tate Gisslen; Sally-Anne Stephenson; Alan H Jobe; Christine L Knox
Journal:  Front Cell Infect Microbiol       Date:  2017-04-13       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.